发明名称 Piperazines, pharmaceutical compositions and methods of use thereof
摘要 Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.
申请公布号 US8822472(B2) 申请公布日期 2014.09.02
申请号 US201113069670 申请日期 2011.03.23
申请人 Cornerstone Therapeutics, Inc. 发明人 Clark Roger B.;Elbaum Daniel
分类号 A61K31/497;C07D401/08;C07D401/12;C07D413/08;C07D413/12;C07D405/14;C07D241/04;C07D401/14;C07D417/14;C07D513/14;C07D413/14 主分类号 A61K31/497
代理机构 Saul Ewing LLP 代理人 Saul Ewing LLP ;Doyle Kathryn;Silva Domingos J.
主权项 1. A compound of Formula (III) or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, C(═O)R5, C(═O)OR5 and C(═O)NR5R5; V is selected from the group consisting of a bond, C(R4)2, C(R4)2C(R4)2, C(R4)2C(R4)2R6, C(R4)2C(R4)2C(R4)2R6, C(═O), C(═O)R6, C(═S), C(═S)R6, CH2C(═O), CH2C(═O)R6, CH2C(═S), CH2C(═S)R6, SO2, and SO2R6; A is a linking —C(Ra)2—Xa—; Xa is selected from the group consisting of O, C(R4)2O, OC(R4)2, NR5, C(═O), C(R4)2C(═O), C(═O)NR5, C(R4)2NR5, NR5C(R4)2, NR5C(═O), NR5C(═O)C(R4)2, S, C(R4)2S, and SC(R4)2; when Xa is C(R4)2O, C(R4)2NR5, C(═O), C(R4)2C(═O), C(═O)NR5 or C(R4)2S, then each Ra is independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R7, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R8, C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R8, halo, haloalkyl, OR5, SR5, NR5R5, C(═O)OR5, NO2, CN, C(═O)R5, C(═O)C(═O)R5, C(═O)NR5R5, N(R5)C(═O)R5, NR5S(═O)nR5, N(R5)C(═O)OR5, NR5C(═O)C(═O)R5, NR5C(═O)R5, NR5S(O)nNR5R5, NR5S(═O)nR5, S(═O)nR5, S(═O)nNR5R5 and OC(═O)R5, or both Ra are taken together to form a 3 to 6 membered ring containing 0 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein said ring is substituted with one or more R8; and, when Xa is O, OC(R4)2, NR5, N5C(R4)2NR5C(═O), NC(═O)R5C(R4)2, S, or SC(R4)2, then each Ra is independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R7, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R8, C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R8, haloalkyl, C(═O)OR5, CN, C(═O)R5, C(═O)C(═O)R5 and C(═O)NR5R5, or both Ra are taken together to form a 3 to 6 membered ring containing 0 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein said ring is substituted with one or more R8; each R4 is independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R7, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R8, C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R8, halo, haloalkyl, OR5, SR5, NR5R5, C(═O)OR5, NO2, CN, C(═O)R5, C(═O)C(═O)R5, C(═O)NR5R5, N(R5)C(═O)R5, NR5S(═O)nR5, NR5C(═O)OR5, NR5C(═O)C(═O)R5, NR5C(═O)R5, NR5S(═O)nNR5R5, NR5S(═O)nR5, S(═O)R5, S(═O)nNR5R5 and OC(═O)R5, or two R4 are taken together to form a 3-6 membered ring comprising 0-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of N, O and S, and wherein said ring is substituted with one or more R8; each R5 is independently selected from the group consisting of H, C1-C10 alkyl and C2-C10 alkenyl; each R6 is independently selected from the group consisting of C(R4)2, C(R4)2C(R4)2, NR5, O, C(═O), C(═O)C(R4)2, C(═O)O, OC(R4)2, C(R4)2O, C(R4)2S, C(R4)2NR5, NR5CH2, S and SC(R4)2; each R7 is independently selected from the group consisting of halo, haloalkyl, OR5, SR5, C(═O)R5, OC(═O)R5, C(═O)OR5, NR5R5, NO2, CN, OC(═O)NR5R5, C(═O)NR5R5, N(R5)C(═O)R5, NR5C(═O)OR5, S(═O)nNR5R5, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, 3-8 membered heterocycloalkyl, 4-10 membered heterocycloalkenyl, C5-C11 bicycloalkyl, C5-C11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, aryl, and heteroaryl, wherein said aryl and heteroaryl are each optionally substituted with one or more R9; each R8 is independently selected from the group consisting of R7, C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, and C2-C10 alkynyl substituted with one or more R7; each R9 is independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R7, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R8, C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R8, 3-8 membered heterocycloalkyl, 3-8 membered eterocycloalkyl substituted with one or more R8, 4-10 membered heterocycloalkenyl, 4-10 membered heterocycloalkenyl substituted with one or more R8, C5-C11 bicycloalkyl, C5-C11 bicycloalkyl substituted with one or more R8, C5-C11 bicycloalkenyl, C5-C11 bicycloalkenyl substituted with one or more R8, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkyl substituted with one or more R8, 5-11 membered heterobicycloalkenyl, 5-11 membered heterobicycloalkenyl substituted with one or more R8, halo, OR5, SR5, NR5R5, C(═O)OR5, NO2, CN, C(═O)R5, C(═O)C(═O)R5, C(═O)NR5R5, NR5C(═O)R5, NR5S(═O)nR5, NR5C(═O)OR5, NR5C(═O)C(═O)R5, NR5C(═O)NR5R5, NR5S(═O)nNR5R5, NR5S(═O)nR5, S(═O)nR5, S(═O)nNR5R5, OC(═O)R5, optionally substituted aryl, and optionally substituted heteroaryl; R12 is selected from the group consisting of:wherein in R12: (a) W is selected from the group consisting of NR5, O and S; (b) each m is an integer from 0 to 3; (c) each p is an integer from 0 to 5; (d) each q is an integer from 0 to 4; (e) each t is an integer from 0 to 2; and (f) each R9 is independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, halo, OR5, NR5R5, C(═O)OR5, NO2, CN, S(═O)nR5 optionally substituted aryl and optionally substituted heteroaryl; and each R13 independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with one or more R7, C2-C10 alkenyl, C2-C10 alkenyl substituted with one or more R7, C2-C10 alkynyl, C2-C10 alkynyl substituted with one or more R7, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted with one or more R8, C4-C10 cycloalkenyl, C4-C10 cycloalkenyl substituted with one or more R8, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkyl substituted with one or more R8, 4-10 membered heterocycloalkenyl, 4-10 membered heterocycloalkenyl substituted with one or more R8, C5-C11 bicycloalkyl, C5-C11 bicycloalkyl substituted with one or more R8, C5-C11 bicycloalkenyl, C5-C11 bicycloalkenyl substituted with one or more R8, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkyl substituted with one or more R8, 5-11 membered heterobicycloalkenyl, 5-11 membered heterobicycloalkenyl, 5-11 membered heterobicycloalkenyl substituted with one or more R8, halo, OR5, SR5, NR5R5, C(═O)OR5, NO2, CN, C(═O)R5, C(═O)C(═O)R5, C(═O)NR5R5, NR5C(═O)R5, NR5S(═O)nR5, NR5C(═O)OR5, NR5C(═O)C(═O)R5, NR5C(═O)NR5R5, NR5S(═O)nNR5R5, NR5S(═O)nR5, S(═O)nR5, S(═O)nNR5R5, OC(═O)R5, optionally substituted aryl and optionally substituted heteroaryl; n is 1 or 2; and q is an integer from 0 to 4.
地址 Cary NC US